09:24 AM EDT, 06/07/2024 (MT Newswires) -- ChromaDex ( CDXC ) said Friday that the US Food & Drug Administration has granted orphan-drug designation and rare pediatric disease designation for NRC, the company's drug candidate to treat Ataxia Telangiectasia.

Ataxia Telangiectasia is a rare, progressive disease that is characterized by neurological and immunological symptoms.

The company said it plans to file an investigational new-drug application with the FDA in anticipation of conducting human clinical trials.

Shares of ChromaDex ( CDXC ) were up nearly 11% in recent premarket activity.

Price: 3.1700, Change: +0.31, Percent Change: +10.84